![](/img/cover-not-exists.png)
Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses
Lampert, Erika J, Cimino-Mathews, Ashley, Lee, Joo Sang, Nair, Jayakumar, Lee, Min-Jung, Yuno, Akira, An, Daniel, Trepel, Jane B, Ruppin, Eytan, Lee, Jung-MinVolume:
8
Journal:
Journal for ImmunoTherapy of Cancer
DOI:
10.1136/jitc-2019-000516
Date:
July, 2020
File:
PDF, 1.15 MB
2020